[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582167":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":22,"locations":23,"responsibleParty":156,"collaborators":22,"id":158,"slug":22,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":22,"eligibilityCriteria":163,"healthyVolunteers":159,"sex":164,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":22,"studyType":170,"phases":171,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":26,"whyStopped":22,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},{"fullName":5,"class":6},"Sound Pharmaceuticals, Incorporated","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open Label","EXPERIMENTAL","Oral administration of SPI-1005 400 mg BID",[13],"Drug: Ebselen",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ebselen","Glutathione peroxidase mimetic",[9],[21],"SPI-1005",null,[24,44,59,70,85,96,111,126,141],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"The House Institute","RECRUITING","Los Angeles","California","90057","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-118.24368,34.05223,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":22,"email":43},"Study Coordinator","CONTACT","(213) 443-8193","clinicaltrials@hifla.org",{"facility":45,"status":26,"city":46,"state":47,"zip":48,"country":30,"countryCode":31,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"ENT and Allergy Associates of Florida","Boynton Beach","Florida","33471",{"type":33,"coordinates":50},[51,52],-80.06643,26.52535,{"lat":52,"lon":51},[55],{"name":56,"role":41,"phone":57,"phoneExt":22,"email":58},"Clinical Research Supervisor","954-575-9301","pamanley@entaaf.com",{"facility":45,"status":26,"city":60,"state":47,"zip":61,"country":30,"countryCode":31,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Delray Beach","33484",{"type":33,"coordinates":63},[64,65],-80.07282,26.46146,{"lat":65,"lon":64},[68],{"name":56,"role":41,"phone":69,"phoneExt":22,"email":58},"(561) 939 - 0186",{"facility":71,"status":26,"city":72,"state":73,"zip":74,"country":30,"countryCode":31,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Northwell Health","New Hyde Park","New York","11042",{"type":33,"coordinates":76},[77,78],-73.68791,40.7351,{"lat":78,"lon":77},[81],{"name":82,"role":41,"phone":83,"phoneExt":22,"email":84},"Clinical Research Manager","718-470-7974","gmullool@northwell.edu",{"facility":86,"status":26,"city":73,"state":73,"zip":87,"country":30,"countryCode":31,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"ENT and Allergy Associates, LLP","10017",{"type":33,"coordinates":89},[90,91],-74.00597,40.71427,{"lat":91,"lon":90},[94],{"name":95,"role":41,"phone":83,"phoneExt":22,"email":84},"Ginny Mullooly",{"facility":97,"status":26,"city":98,"state":99,"zip":100,"country":30,"countryCode":31,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Thomas Jefferson University","Philadelphia","Pennsylvania","19107",{"type":33,"coordinates":102},[103,104],-75.16362,39.95238,{"lat":104,"lon":103},[107],{"name":108,"role":41,"phone":109,"phoneExt":22,"email":110},"Maya Childs","(215) 955-6760","Maya.Childs@jefferson.edu",{"facility":112,"status":26,"city":113,"state":114,"zip":115,"country":30,"countryCode":31,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Medical University of South Carolina","Charleston","South Carolina","29425",{"type":33,"coordinates":117},[118,119],-79.93275,32.77632,{"lat":119,"lon":118},[122],{"name":123,"role":41,"phone":124,"phoneExt":22,"email":125},"Research Director","(843)792-1356","nguyensh@musc.edu",{"facility":127,"status":26,"city":128,"state":129,"zip":130,"country":30,"countryCode":31,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"University of Texas Southwestern","Dallas","Texas","75390",{"type":33,"coordinates":132},[133,134],-96.80667,32.78306,{"lat":134,"lon":133},[137],{"name":138,"role":41,"phone":139,"phoneExt":22,"email":140},"Paula Arellano-Cruz","214-648-8096","paula.arellano-cruz@utsouthwestern.edu",{"facility":142,"status":26,"city":143,"state":144,"zip":145,"country":30,"countryCode":31,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Medical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":33,"coordinates":147},[148,149],-87.90647,43.0389,{"lat":149,"lon":148},[152],{"name":153,"role":41,"phone":154,"phoneExt":22,"email":155},"Clinical Research Coordinator","414.955.0822","smleziva@mcw.edu",{"type":157,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100582167",false,"NCT06859788","SPI-1005 for the Treatment of Meniere's Disease (Open Label)","Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease","Inclusion Criteria:\n\n* Adult males\u002Ffemales, 18-75 years of age at the time of enrollment.\n* Diagnosis of probable or definite Meniere's Disease by AAO-HNS Amended 2015 Criteria.\n* At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Meniere's disease, within 3 months of study enrollment.\n* Type A tympanogram at screening.\n* Air conduction thresholds ≤ 90 dB at all tested frequencies (250-8000 Hz) in both ears.\n* Subject is willing and able to provide informed consent and perform study procedures and assessments per protocol.\n* Reproductive requirements\n\nExclusion Criteria:\n\n* Current, or within 60 days prior to study enrollment, use of IV or intratympanic ototoxic medications such as chemotherapy including cisplatin, carboplatin, or oxaliplatin; aminoglycoside antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or loop diuretics including furosemide.\n* History of otosclerosis or vestibular schwannoma.\n* History of significant middle ear or inner ear surgery in the affected ear.\n* Conductive hearing loss with air-bone gap ≥15 dB, otitis media, or mixed hearing loss.\n* Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological, or psychiatric disease.\n* Current use or within 30 days prior to study enrollment systemic steroids.\n* Current use or within 7 days prior to study enrollment intratympanic steroids.\n* Hypersensitivity or idiosyncratic reaction to compounds related to ebselen or excipients.\n* Female patients who are pregnant or breastfeeding.\n* Participation in another investigational drug or device study within 30 days prior to study consent.\n* Participant resides more than 100 miles from the study site.","ALL","18 Years","75 Years",{"count":168,"type":169},200,"ESTIMATED","INTERVENTIONAL",[172],"PHASE3","Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.",[175,176],"Meniere's Disease","Ménière's Disease",[178,179,180,181,182,21],"ebselen","hearing loss","tinnitus","vertigo","dizziness","2026-06-01",{"date":185,"type":186},"2026-06-02","ACTUAL",{"date":188,"type":186},"2025-10-29",{"date":190,"type":169},"2026-12",{"name":5,"class":6},9]